- Login
- Register & Subscribe
- Language: EN FR DE
Thursday 25 April 2013
Novartis has confirmed that sales will be flat this year as the loss of revenue from generic competition offsets growth from its patent-protected portfolio. The revenue impact of generic competition is expected to be about $3.5 billion.
Country: Switzerland
Thursday 25 April 2013
The loss of patents on big revenue-generating medicines continued to weigh on AstraZeneca Plc as first-quarter revenue declined by 12% at constant exchange rates to $6.4 billion and core operating profit declined by 21% to $2.3 billion. The company expects that revenue for the year as a whole will decline by a mid-to-high single digit percentage.
Country: United Kingdom
Wednesday 24 April 2013
GlaxoSmithKline Plc said it expects sales to grow by around 1% at constant exchange rates this year, despite a first-quarter outturn in which both turnover and operating profit declined. The quarterly performance was affected by one-off developments including the divestment of the group’s non-core over-the-counter medicines.
Country: United Kingdom
Wednesday 24 April 2013
A therapeutic vaccine for human papillomavirus (HPV) that is being developed by Genticel SA of France has received backing by a syndicate led by Wellington Partners, raising €18.2 million in new capital.
Country: France
Monday 22 April 2013
Scientists at The Scripps Research Institute in La Jolla, California have discovered an antibody that can trigger the transformation of bone marrow stem cells directly into brain cells – something that reportedly has not been done before.
Country: United States
Monday 22 April 2013
TiGenix NV has reported that a Phase 2a study of its allogeneic stem cell therapy in patients with refractory rheumatoid arthritis had positive six-month safety data. The trial enrolled patients who had failed to respond to at least two biologic therapies.
Country: Belgium
Monday 22 April 2013
The German molecular diagnostics company, Curetis AG, has raised €12.5 million in a Series B round to further test and commercialise its technology for detecting antibiotic resistant bacteria. The round was led by HBM Partners of Switzerland.
Country: Germany
Monday 22 April 2013
The Board of Directors of Elan Corporation Plc has formally rejected an unsolicited takeover bid from the US investment group, Royalty Pharma, saying it substantially undervalues the company. This follows a low turnout in a share buyback.
Country: Ireland
Sunday 21 April 2013
The importance of next-generation gene sequencing technologies has been underscored once again with Thermo Fisher Scientific’s announcement of plans to acquire Life Technologies Corp for $13.6 billion.
Country: United States
Friday 19 April 2013
Shareholders of Elan Corporation Plc appear to have rebuffed an unsolicited takeover bid from the US financial group, Royalty Pharma, which valued the Ireland-based company at up to $12 per share for a total enterprise value of up to $7.3 billion.
Country: Ireland
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013